Psoriasis is a chronic inflammatory skin disease affecting 2-3% of the population. Certain systemic drugs currently available for its treatment could be associated, in the long term, with organ toxicity and adverse events, thus, clinical monitoring throughout treatment is required. Moreover, tolerability issues, parenteral administration, and barriers to patient access, such as high cost and specialist management lead to treatment failure.

Pharmacodynamic assessment of apremilast for the treatment of moderate-to-severe plaque psoriasis

ROMANELLI, MARCO;CHIRICOZZI, ANDREA
2016-01-01

Abstract

Psoriasis is a chronic inflammatory skin disease affecting 2-3% of the population. Certain systemic drugs currently available for its treatment could be associated, in the long term, with organ toxicity and adverse events, thus, clinical monitoring throughout treatment is required. Moreover, tolerability issues, parenteral administration, and barriers to patient access, such as high cost and specialist management lead to treatment failure.
2016
Bianchi, Luca; Del Duca, Ester; Romanelli, Marco; Saraceno, Rosita; Chimenti, Sergio; Chiricozzi, Andrea
File in questo prodotto:
File Dimensione Formato  
Pharmacodynamic assessment of apremilast for the treatment of moderate to severe plaque psoriasis.pdf

Open Access dal 01/10/2017

Tipologia: Documento in Post-print
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 743.49 kB
Formato Adobe PDF
743.49 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11568/796500
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 16
  • ???jsp.display-item.citation.isi??? 16
social impact